🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — July 08, 2026

The July 8, 2026, small-cap biotech approval stream delivered five biosimilar/other approvals with zero NMEs, zero label expansions, and zero biosimilar designations, resulting in a uniformly neutral signal set. The dominant theme is generic/biosimilar market expansion across diverse therapeutic areas—metabolic (liraglutide), neurology (brivaracetam), cardiovascular (chlorthalidone), and ophthalmology (brimonidine tartrate)—with no single therapeutic cluster emerging as a sector signal. The highest-conviction event is SANDOZ’s approval for liraglutide, which signals incremental competitive pressure on the GLP-1 class, though without disclosed sales estimates or exclusivity details, commercial impact remains unquantifiable. Key risk: the absence of any NME or breakthrough therapy approvals in this period highlights a lack of high-value innovation catalysts for small-cap sponsors, reinforcing a cautious near-term outlook for the sub-sector.

5 total filings
· daily

Significant Contract Modifications ($10M+) — July 08, 2026

This digest of 13 government contracts, totaling $1.16 billion in obligations from July 8, 2026, reveals a heavily civilian-dominated procurement landscape, with only one defense-related award. The Department of Homeland Security (DHS) is the dominant spender, accounting for five contracts worth $447.5 million, led by TSA baggage screening and ICE detention medical and cyber support. The highest-conviction signal is the $94.7 million sole-source award to TRM LABS, INC. for DHS cyber disruption support, indicating urgent, non-competitive demand for specialized cyber analytics. A key risk is the high execution risk on TRM LABS' fixed-price, one-year contract, which could pressure margins for this small business. Overall, the digest signals stable civilian agency spending on IT, security, and healthcare staffing, with limited direct defense sector exposure.

13 total filings
· daily

New Drug Approvals (Original) — July 08, 2026

The July 8, 2026, FDA approval digest is dominated by five biosimilar/other approvals, with zero NMEs, zero label expansions, and zero biosimilars (as classified by the stream), resulting in a neutral signal across the board. The period lacks high-conviction catalysts, as all approvals are FALLBACK-type generics or biosimilar equivalents for established molecules: LEVOCARNITINE (Baxter Healthcare), BRIVARACETAM (ScieGen Pharms), CHLORTHALIDONE (Macleods Pharma), BRIMONIDINE TARTRATE (Saba Ilac Sanayi), and LIRAGLUTIDE (Sandoz). The most notable commercial signal is Sandoz’s approval for LIRAGLUTIDE, which enters the high-value GLP-1 biosimilar market, posing a bearish risk to Novo Nordisk’s originator franchise (Victoza/Saxenda). The key risk is that these are low-materiality, non-innovative approvals with no disclosed peak sales estimates, offering limited differentiation for investors. No IRA exposure flags are triggered as all are off-patent generics or biosimilars with no remaining exclusivity.

5 total filings
· daily

Contract Deobligations Alert — July 08, 2026

This digest of 13 government contract obligations totaling $1.16 billion reveals a civilian-agency-dominated procurement environment, with only 1 of 13 awards defense-related (DHS/TSA). The dominant sector theme is federal IT and healthcare services, led by DHS (5 contracts, $407M aggregate) and HHS (4 contracts, $328M aggregate). The highest-conviction signal is the $94.7M sole-source cyber support award to TRM LABS, INC. by DHS/ICE, indicating urgent capability needs. Key risks include concentration in civilian agency budgets vulnerable to Continuing Resolution uncertainty and execution risk on fixed-price contracts like BAE Systems' $97.6M FEMA IT award where only 38% of funds are outlayed. The aggregate signal strength of 5.4/10 reflects a neutral-to-mildly-bullish tone with no bearish signals identified, but investors should monitor re-compete dates and option exercises for revenue visibility.

13 total filings
· daily

Contract Option Exercises — July 08, 2026

This digest covers 13 contract option exercises totaling $1.159 billion, with only 1 defense-related award (8% of total value) and the remainder concentrated in civilian agencies, primarily DHS ($380M across 4 contracts) and HHS ($328M across 4 contracts). The dominant theme is sustained civilian IT and healthcare services spending, with notable sole-source awards to TRM LABS ($94.7M) and The Aerospace Corporation ($141.2M) signaling niche capabilities. The highest-conviction signal is the bullish competitive win for Deloitte ($86.1M obligated) in HHS identity management, while the key risk is the non-competitive, fixed-price award to TRM LABS, which carries high execution risk for a small business. Investors should monitor DHS/ICE detention healthcare spending (Amergis, $97.4M) and the re-compete of Booz Allen’s CMS cloud contract (July 2026).

13 total filings
· daily

Federal Professional Services Contracts — July 08, 2026

The sole contract in this digest, a $126.2 million firm-fixed-price delivery order awarded to VERTEX AEROSPACE LLC by the Transportation Security Administration (DHS), represents a pure civilian agency security infrastructure play with zero defense exposure. The contract is for Checked Baggage Inspection System (CBIS) remediation, a security-critical program with $106.4 million already outlayed, signaling high execution certainty and a stable multi-year revenue stream for VERTEX through July 2026. The neutral signal strength (6/10) reflects the moderate risk of a fixed-price structure and full-and-open competition, balanced against the long-term visibility and sustained demand from TSA's aviation security priorities. Key risks include potential budget reallocations within DHS and the absence of a competitive moat signal, as the award was competitively won.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 08, 2026

This digest covers $556.8 million in federal IT and cybersecurity contracts awarded between 2022 and 2026, with zero defense-related awards, underscoring a purely civilian procurement focus. The dominant theme is health IT modernization, driven by the Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS), which account for $250.2 million (45%) of total obligation across three contracts to Deloitte, Booz Allen Hamilton, and ESIMPLICITY. The highest-conviction signal is Deloitte's $86.1 million HSPD-12 identity management win, a competitive award with strong funding commitment ($65M outlaid) and sustained demand from a mandated program. A key risk is the concentration of awards among small businesses (TRM LABS, TISTA, ESIMPLICITY, INSERSO) that face execution risk on fixed-price or time-and-materials contracts, particularly TRM LABS' $94.7 million sole-source award with high pricing risk.

7 total filings
· daily

NASA & Space Contracts Intelligence — July 08, 2026

The single contract in this digest, a $141.2 million sole-source award to The Aerospace Corporation by NASA, represents a mature, largely completed engagement with no immediate upside for public equity investors. The contract is entirely civilian (NASA) and non-competitive, signaling stable but capped revenue for a nonprofit entity. The highest-conviction signal is neutral, reflecting low performance risk but zero competitive growth catalyst. The key risk is the lack of follow-on contract visibility post-September 2024, which could create a revenue gap for the contractor.

1 total filings
· daily

All HHS Contracts — July 08, 2026

This digest of four HHS contracts totaling $327.7 million reveals a clear civilian health IT spending theme, with zero defense exposure. The highest-conviction signal is Deloitte’s $86.1 million HSPD-12 identity management win, a competitive, fixed-price award indicating strong federal IT services positioning. Booz Allen’s $84M cloud-based Marketplace integration contract for CMS reinforces sustained health IT investment but lacks multi-year visibility. ESIMPLICITY’s $80.1M T-MSIS award highlights small, woman-owned 8(a) contractor growth in targeted Medicaid data systems, though concentration risk is elevated. Leidos Biomedical’s $77.6M cost-plus NIH contract offers low execution risk but neutral near-term catalysts. Key risk: four contracts face medium pricing risk (fixed-price or T&M) and uncertain re-compete timelines post-2026.

4 total filings
· daily

All DOE Contracts — July 08, 2026

The sole contract awarded on July 8, 2026, is a $62.6 million initial obligation from the Department of Energy (DOE) to West Valley Cleanup Alliance, LLC for environmental remediation at the West Valley Demonstration Project, with a potential total value of $392.2 million over four years. This is a purely civilian contract with no defense-related content, reflecting stable DOE environmental management funding. The cost-plus-award-fee structure reduces contractor risk and suggests predictable margins, but the recipient is a private LLC, limiting direct public equity exposure. The key risk is the reliance on option exercises tied to future DOE budget allocations, while the highest-conviction signal is the low pricing risk for the contractor. Investors should monitor DOE environmental management appropriations and any subcontractor awards that could provide indirect public company exposure.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 08, 2026

The two contracts analyzed total $267.3 million in obligations, split evenly between defense-related (NASA) and civilian (DHS/TSA) agencies. The dominant theme is stable, multi-year infrastructure and engineering services spending, with The Aerospace Corporation’s $141.2 million NASA contract and Vertex Aerospace LLC’s $126.2 million TSA contract both nearing full funding utilization. The highest-conviction signal is Vertex Aerospace’s firm-fixed-price TSA award, which offers strong execution leverage and near-complete funding certainty. Key risks include the lack of competitive moat signals for either contractor and the potential for budget reallocation under a continuing resolution, which could delay follow-on awards for both programs.

2 total filings
· daily

High-Value Federal Grants ($5M+) — July 08, 2026

This digest covers 13 high-value federal grants totaling $1.16 billion, with only one defense-related award (The Aerospace Corporation at NASA, $141M) and the vast majority flowing to civilian agencies, led by DHS ($383M across five contracts) and HHS ($328M across four contracts). The highest-conviction signal is a bullish one for Deloitte & Touche LLP ($86M HHS identity management contract) and ESIMPLICITY Inc ($80M CMS health IT contract), both reflecting durable civilian IT modernization mandates. Key risks include execution risk on TRM LABS' $94.7M sole-source cyber contract and budget uncertainty for FEMA and ICE contracts tied to discretionary appropriations. Investors should watch for option exercises on Leidos Biomedical Research ($77.6M base) and Accenture Federal Services ($66.2M FBI contract) as catalysts for revenue visibility.

13 total filings
· daily

DOE Energy Grants — July 08, 2026

The single contract in this digest, a $62.6 million initial obligation from the Department of Energy to West Valley Cleanup Alliance, LLC for environmental remediation, highlights a civilian-sector theme of stable, long-duration cleanup work. With zero defense-related awards, the digest is entirely civilian, and the cost-plus-award-fee structure reduces contractor risk. The highest-conviction signal is the potential $392.2 million total value over four years, but the private nature of the recipient limits direct public equity exposure. A key risk is the reliance on DOE budget allocations for option exercise, which could be affected by broader fiscal policy shifts.

1 total filings
· daily

General Federal Contracts — July 08, 2026

This digest covers 13 federal contracts totaling $1.16 billion, with a heavy civilian tilt (12 of 13 awards) and only one defense-related contract. The dominant theme is sustained civilian agency IT and security spending, particularly from DHS (five awards totaling $383M) and HHS (four awards totaling $328M). The highest-conviction signal is the $94.7M sole-source award to TRM LABS, INC. for DHS cyber analytical support, which indicates a unique capability or urgent need but carries high execution risk due to its fixed-price, non-compete structure. A key risk is the concentration of awards to small or private entities (TRM LABS, ESIMPLICITY, INSERSO), limiting direct public market exposure and raising execution concerns. No bearish signals were identified, but neutral ratings on 11 contracts suggest limited upside surprise potential.

13 total filings
· daily

All NASA Contracts — July 08, 2026

This digest covers a single NASA contract totaling $141.2 million, awarded to The Aerospace Corporation for specialized engineering services under the NSEETS program. The contract is 100% defense-related (by PSC code AD24), though the agency is civilian (NASA). The highest-conviction signal is neutral: the sole-source, cost-plus-fixed-fee structure provides stable, low-risk revenue but limits upside surprise, and the contract appears largely complete with $141 million already outlayed. Key risk is the lack of follow-on contract visibility after September 2024, which could create a revenue gap for the contractor. The aggregate signal strength is a moderate 5.0/10, reflecting no clear bullish or bearish catalysts from this single award.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 08, 2026

The five filings for July 8, 2026, reveal a concentrated pattern of insider selling within the S&P 500 Technology sector, particularly at Snowflake Inc., where a director executed a large, pre-planned sale of nearly $5 million in stock. This activity, while conducted under a Rule 10b5-1 plan, signals a potential peak in management's valuation expectations for the stock. A separate, smaller sale by a Palo Alto Networks director adds to the bearish insider sentiment. In contrast, a routine Schedule 13G/A filing from BlackRock for Autodesk confirms a significant passive stake of 11.0%, indicating institutional confidence in the company's long-term value without any intent to influence control. The overall portfolio-level theme is one of caution, with insider selling dominating the day's disclosures, suggesting that company insiders may be taking profits or hedging against near-term headwinds in the tech sector. No forward-looking guidance, capital allocation changes, or M&A activity were reported in these filings, making the insider trading patterns the most actionable intelligence for investors.

4 high priority 1 medium 5 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 08, 2026

The three NASDAQ-100 filings reveal a mixed picture for the consumer and technology sectors. Costco's routine dividend declaration signals stable capital returns but lacks growth catalysts, while insider selling at both Starbucks and Meta Platforms raises caution flags. The insider transactions, all executed under Rule 10b5-1 plans, suggest pre-planned diversification rather than panic, but the timing and magnitude—particularly Meta's COO selling over $1.25M—warrant attention. No period-over-period comparisons or forward-looking guidance were available in these filings, limiting trend analysis. The key takeaway is a divergence between steady shareholder returns (Costco) and insider profit-taking at high valuations (Starbucks, Meta), which could signal near-term headwinds for growth stocks. Investors should monitor upcoming earnings calls for context on these insider moves and any guidance changes.

2 high priority 1 medium 3 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 08, 2026

This digest of 50 filings reveals a dominant pattern of passive institutional ownership updates, with FMR LLC (Fidelity) and BlackRock, Inc. accounting for the vast majority of filings, signaling a routine mid-year rebalancing period. A critical outlier is the activist situation at SCHMID Group N.V., where a controlling shareholder group has consolidated a 40.25% stake through a complex restructuring, presenting both significant control and future dilution risks. The most notable insider activity is a bearish signal from Silence Therapeutics, where a major shareholder sold $16.3M in stock over a week, reducing a substantial position. Period-over-period comparisons from Fidelity and BlackRock filings show mostly stable percentage ownership, but with notable increases in absolute share counts at Lumentum (+8.9%), Roku (+13.3%), and Monolithic Power Systems, indicating strategic accumulation. Conversely, Fidelity trimmed positions in Genpact (-2.3%) and Cytokinetics (now below 5%), suggesting selective sector rotation. The data highlights a bifurcated market where mega-cap asset managers are making granular adjustments, while a few companies face concentrated ownership and potential governance events.

3 high priority 47 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 08, 2026

The three S&P 500 Financials filings for July 8, 2026, reveal a sector-wide pattern of insider selling at financial institutions, with Capital One Financial and Mastercard both reporting Rule 10b5-1 plan sales by senior officers. While these transactions are pre-planned and thus less indicative of immediate bearish sentiment, the aggregate volume and timing suggest a cautious posture among insiders at the peak of the current market cycle. JPMorgan Chase's filing is a routine beneficial ownership report with no material trading activity, providing a neutral anchor. The lack of any period-over-period comparisons, forward-looking guidance, or capital allocation actions across these filings limits the depth of trend analysis, but the insider activity pattern is the dominant signal. The sector appears to be in a wait-and-see mode, with no bullish catalysts emerging from these disclosures, reinforcing a neutral-to-cautious outlook for large-cap financials in the near term.

3 high priority 3 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 08, 2026

The three filings for the S&P 500 Consumer Staples sector on July 8, 2026, present a mixed but largely low-volatility picture. The dominant theme is capital return, with Costco declaring a routine quarterly dividend of $1.47 per share, reinforcing the sector's defensive income profile. However, the most actionable signal comes from Conagra Brands, where BlackRock's amended 13G filing reveals a significant 13.5% passive stake, signaling institutional conviction in the packaged food segment. This is partially offset by a bearish insider signal from Hershey, where the controlling Milton Hershey Trust sold shares under a 10b5-1 plan, representing a modest but notable reduction in insider holdings. The filings lack period-over-period comparisons or forward-looking guidance, limiting trend analysis, but the combination of a major passive accumulation and a controlled insider sale suggests a sector in a stable, income-focused phase with selective institutional interest.

1 high priority 2 medium 3 total filings